"The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.
HER2 is a protein involved in normal cell growth. It is foun"...
(Generic versions may still be available.)
Teslac Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Teslac (testolactone) is an anticancer (antineoplastic) drug used to treat some types of breast cancer. The brand name of this medication is discontinued, but generic versions may be available. Side effects include allergic reactions (difficulty breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), new breast lumps, bone pain, menstrual changes, abnormal vaginal bleeding, vaginal discharge, pelvic pain or pressure, excessive nausea, vomiting, or thirst.
The recommended oral dose of Teslac is 250 mg four times a day. Teslac may interact with estrogen, birth control pills containing estrogen, or blood thinners. Tell your doctor all medications and supplements you use. It is unknown if Teslac will be harmful to a fetus. Do not take this medication without first talking to your doctor if you are pregnant or could become pregnant during treatment. This drug passes into breast milk in small amounts and may affect a nursing baby. Consult your doctor before breastfeeding.
Our Teslac (testolactone) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Teslac FDA Prescribing Information: Side Effects
Certain signs and symptoms have been reported in association with the use of this drug but, in these instances, it is often impossible to determine the relationship of the underlying disease and drug administration to the reported reaction. Such reactions include maculopapular erythema, increase in blood pressure, paresthesia, malaise, aches and edema of the extremities, glossitis, anorexia, and nausea and vomiting. Alopecia alone and with associated nail growth disturbance have been reported rarely; these side effects subsided without interruption of treatment.
Drug Abuse And Dependence
TESLAC (testolactone) is classified as a controlled substance under the Anabolic Steroids Control Act of 1990 and has been assigned to Schedule III.
Read the entire FDA prescribing information for Teslac (Testolactone) »
Additional Teslac Information
Report Problems to the Food and Drug Administration
Find support and advances in treatment.